GIS trade ideas
GILEAD SCIENCES (GILD) buy signals on D1.GILEAD SCIENCES, daily timeframe: Support line + Side of Bollinger bands + Nice discount + Divergence + Hammer
GIILD 12.08.20 LongAsset and Time frame -GILD,4H
Entry Price -68.99
Exit(Stop Loss) -67.19
Exit(Take Profit) -75.55
Technical Analysis -Price reacted to the -27.2 for the second time(less favorable) but had a hard time going even more downwards, on the 4H chart price has left the tunnel with a gap up, on weekly chart price is sitting on the 100SMA, also RSI divergence
What can be improved -
Conclusion & End of Trade -
GILD starting to look niceThis has pulled right back into the Demand Zone. Looking to start buying here
Remdesivir News is GOOD for Gilead - 4HR ChartHearing chatter down the grape vine about Remdesivir again, watch for the bounce back-up on GILD. This was just trading in the $80 dollar range so keep an eye out for that move on the news.
Ahmed Jarmouni Given the good announcement, it is advisable to buy this share
But beware, she has to break higher than yesterday's fence:
Gilead Sciences, Inc
GILD
announced Monday it was seeking complete FDA approval for its drug Remdesivir, which is being used in the treatment of COVID-19.
GIILD 05.08.20 LongAsset and Time frame - Daily
Entry Price -70.88
Exit(Stop Loss) -68.13
Exit(Take Profit) -80.41
Technical Analysis -On the daily chart price reacted to the -27.2 level with an engulfing bullish candle, on the weekly chart theres the 100MA being used as support, and on the 4 hours price reached the -61.8 level
What can be improved -
Conclusion & End of Trade -
GILEAD SCIENCES buy signals on D1.GILEAD SCIENCES, daily timeframe: Support zone + Side of Bollinger Bands + Hammer
ADBE and GILD review, GILD earnings tomorrow, FYIplease follow and subscribe and like if you find helpful , thanks RICK
GILEAD BUYGilead is giving a re entry point here.
AT:
Price its un compressing , has break the trendLine giving us a good RR entry.
Fundamentals:
July 22 is the earning report ,the US government has purchased all available stock of the remdesivir vaccine.
Enjoy profits , and don't forget to follow us for more ! :D
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients.
On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%.
The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it.
On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish
Volume, Bullish
PMO, Bullish
MACD, Bullish
RSI, Bullish
OBV, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
very long term playlooks like it may breakout of this range this year... it should be a big one once it really does.. im in over 86-7. goodluck
Gilead is heading to the all time high Gilead Sciences is one of the largest antiviral producers in the world. Covid 19 pandemic showed that the greatest threat to the existence of humanity comes from Viral infections not wars or other natural disasters.
Gilead has hundreds of untested patented antiviral agents that can helps in these kind of situations. Finding the cure for the hardest diseases like HIV, HCV and now Covid 19, is a good proof how strategic this company is.
Gilead fundamentally is strong too. More than 20B cash in the accounts speeds up the growth. They have bought 3 small cancer research companies in 3 months. In my opinion, Gilead has started a bulish longterm trend and with the help of Remdesivir sales it can reach the all time high.
I m long GILD and I will add to the position if it breaks the resistance at 78.
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
Phase III trials & Chinese red carpet
Buyers maintaining a strong floor.
In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable.
Thus the question, why adding more Gilead?
When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs.
Thanks as usual for keeping the feedback coming 👍 or 👎
